Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Vericel Corporation specializes in advanced cell therapies for the treatment of severe skin injuries and cartilage repair, with a focus on the U.S. market. Its flagship products, Epicel and Carticel, leverage proprietary technology to promote healing, providing a unique competitive advantage in regenerative medicine.
Vericel generates revenue primarily through the sale of its cell therapy products, which are priced at a premium due to their unique regenerative capabilities. The company benefits from strong pricing power and a growing market for advanced therapies, supported by increasing clinical evidence and favorable reimbursement policies.
Regulatory approvals for new indications or products
Sales growth of Epicel and Carticel in the U.S. market
Partnerships or collaborations with larger pharmaceutical companies
Clinical trial results that demonstrate efficacy and safety
Regulatory changes impacting reimbursement for advanced therapies
Technological disruption from emerging regenerative medicine competitors
Increased competition from other biotech firms developing similar therapies
Potential for larger pharmaceutical companies to enter the market
Limited cash flow generation with free cash flow at $0.0B
Dependence on continued revenue growth to fund operations and R&D
low - Vericel's products are essential for patients with severe injuries, making demand relatively inelastic to economic cycles.
Moderate - While Vericel is not highly leveraged, rising interest rates could increase the cost of capital and impact future investment in R&D.
minimal - The company has a low debt-to-equity ratio of 0.27, indicating limited reliance on external financing.
growth - Investors looking for companies with high growth potential in the biotechnology sector.
high - The stock has shown significant price fluctuations, evidenced by a 1-year return of -19.0%.
